Evaluating the cost utility of racecadotril in addition to oral rehydration solution versus oral rehydration solution alone for children with acute watery diarrhea in four low middle-income countries: Egypt, Morocco, Philippines and Vietnam.
J Med Econ
; 25(1): 274-281, 2022.
Article
em En
| MEDLINE
| ID: mdl-35125049
PLAIN LANGUAGE SUMMARYDecision-makers rely on cost utility models to inform decisions about whether to publicly fund treatments as part of Universal Health Care. In low-middle income countries, the capacity to prepare cost utility models may be limited and using existing validated models is a practical solution to assist decision making. This study uses a cost utility model developed and independently validated for the United Kingdom, and adapts it to Philippines, Egypt, Morocco and Vietnam. The model evaluates the clinical benefit and economic impact of using racecadotril in addition to rehydration solution to treat diarrhoea in children. The results show that racecadotril is cost-saving and improves the quality of life for children in Philippines, Egypt, Morocco and Vietnam.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tiorfano
/
Soluções para Reidratação
/
Países em Desenvolvimento
/
Diarreia
/
Antidiarreicos
Tipo de estudo:
Guideline
/
Health_economic_evaluation
/
Health_technology_assessment
/
Prognostic_studies
Limite:
Child
/
Child, preschool
/
Humans
/
Infant
País/Região como assunto:
Africa
/
Asia
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article